BNTX
NASDAQBioNTech SE
Price$88.07-15.74 (-15.16%)
2026-03-042026-06-05
News · 26 weeks63-56%
2025-12-142026-06-07
Mix4890d
- Insider20(42%)
- Other12(25%)
- SEC Filings11(23%)
- Earnings3(6%)
- Analyst2(4%)
Latest news
25 items- PRThe Multi-Billion-Dollar Search for Better Glioblastoma TreatmentsDENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. Yet one of oncology's greatest challenges remains largely unsolved. Glioblastoma. Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with the difficulty of delivering therapies into the brain, has mad
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- PRGlobal Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 TrialFirst investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of carePumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.6% in the non-squamous and 72.7% in the squamous subtypesPumitamig is advancing through a comprehensive global Phase 3 development program in non-small cell lung cancer, including the actively
- ANALYSTBioNTech upgraded by UBS with a new price targetUBS upgraded BioNTech from Neutral to Buy and set a new price target of $135.00
- ANALYSTBernstein initiated coverage on BioNTech with a new price targetBernstein initiated coverage of BioNTech with a rating of Mkt Perform and set a new price target of $96.00
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- PRBioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual MeetingPumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination with chemotherapyGotistobart Phase 2 overall survival data in patients with platinum-resistant ovarian cancer add to the growing body of evidence supporting its potential as a chemotherapy-free treatment optionContinued advancement of late-stage oncology pipeline with 25+ Phase 2 and Phase 3 clinical trials, including 13 ongoing pivotal trials as well as novel-novel combination trials across major cancer types MAINZ, Germany, May 22, 2026 – BioNTech SE (NASDAQ:BNTX, "BioNTech"
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- PRBioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026MAINZ, Germany, May 15, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) held its Annual General Meeting ("AGM") today. A total of 92 per cent of the share capital was represented at the virtual assembly. All resolutions proposed on the agenda items put to the vote at today's AGM were approved by a majority of the shareholders. BioNTech is strengthening its focus on the Company's growing late-stage oncology pipeline, while continuing its discovery and early research aimed at long-term innovation. Consequently, the Company's shareholders approved expanding the Supervisory Board from six to eight members and adding additional expertise: Prof. Iris Löw-Friedrich
- SECAmendment: SEC Form SCHEDULE 13G/A filed by BioNTech SESCHEDULE 13G/A - BioNTech SE (0001776985) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by BioNTech SESCHEDULE 13G/A - BioNTech SE (0001776985) (Subject)
- INSIDERSEC Form 4 filed by Chief Financial Officer Zapata Gomez Ramon4 - BioNTech SE (0001776985) (Issuer)
- INSIDERSEC Form 4 filed by Officer Ryan James Timothy Patrick4 - BioNTech SE (0001776985) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Poetting Sierk4 - BioNTech SE (0001776985) (Issuer)
- INSIDERSEC Form 4 filed by Chief People Officer Jimenez Kylie4 - BioNTech SE (0001776985) (Issuer)
- INSIDERSEC Form 4 filed by Chief Commercial Officer Hanekamp Annemarie4 - BioNTech SE (0001776985) (Issuer)
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- PRBioNTech Announces New ADS Repurchase ProgramMAINZ, Germany, May 7, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) today announced that it has authorized a new share repurchase program (the "Program"), under which the Company may repurchase American Depositary Shares ("ADSs"), each representing one ordinary share of the Company, for an aggregate amount of up to $1.0 billion. Repurchases under the Program may be made until and including May 6, 2027. BioNTech's disciplined approach to capital allocation and strong financial position enables this authorization. BioNTech expects to use the repurchased ADSs to satisfy obligations in the ordinary course of business. The Program is designed to enhance capita
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- PRBioNTech Announces First Quarter 2026 Financial Results and Corporate UpdateFive additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and combination strategy highlighted through multiple clinical data updates, including pumitamig, gotistobart and antibody-drug conjugate programsCatalyst-rich year ahead with six late-stage pipeline data readouts expected across immunomodulators, antibody-drug conjugate and mRNA cancer immunotherapiesCOVID-19 2026/2027 season variant-adapted vaccine development and commercial preparation underwayOperational efficiency to be enhanced through manufacturing footprint consolidation, supporting strategic capital allocation to further advance its growing oncology
- INSIDERChief Operating Officer Poetting Sierk sold $5,527,960 worth of Ordinary Shares (50,000 units at $110.56) (SEC Form 4)4 - BioNTech SE (0001776985) (Issuer)
- PRBioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026MAINZ, Germany, April 21, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this l
- INSIDERAmendment: SEC Form 3 filed by new insider Sahin Ugur3/A - BioNTech SE (0001776985) (Issuer)
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
BNTX FAQ
7 questionsWhat does BioNTech SE do?
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen...Where does BNTX stock trade?
BioNTech SE (BNTX) is listed on NASDAQ.What sector and industry is BNTX in?
BioNTech SE operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did BioNTech SE go public?
BioNTech SE (BNTX) completed its IPO in 2019.What are analysts saying about BNTX?
BioNTech SE has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-05-27.What companies are similar to BNTX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare BNTX side-by-side with any of them on Quantisnow.How can I track BNTX on Quantisnow?
Quantisnow aggregates BioNTech SE's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BNTX to receive live email and push alerts on every new disclosure.